Cancer Nanotechnology in Imaging and Radiotherapy

描述（由申请人提供）：这是建立R25T癌症教育和职业发展计划的提案的第二次修订，癌症纳米技术在成像和放射治疗中的应用。放射学和放射肿瘤学是大量用于癌症诊断和治疗的临床专业，并且可能会因纳米技术的进步而发生革命性变化。为了使纳米技术研究的成果惠及接受放射学或放射肿瘤学服务的患者，物理科学家、肿瘤生物学家和临床医生之间必须密切合作。临床医生最重要的作用是设计和进行临床试验，评估新开发的纳米材料的安全性和有效性。履行这一职责不仅需要临床试验专业知识，还需要熟悉被测纳米材料的物理和化学特性以及临床前研究的结果。在纳米技术研究的概念中，临床医生的投入也是至关重要的，在为这样的研究获得资金时，在临床前研究中，特别是那些涉及动物成像的研究，以及在与监管机构打交道时。充分参与整个法官席？在床边过程中，放射科医生和放射肿瘤学家必须对纳米技术的概念和方法有基本的了解，熟悉纳米技术的安全性和监管问题，并充分掌握肿瘤生物学的原理和实践。此外，他们需要精通临床试验的设计和实施，熟悉小动物成像，并能够撰写研究赠款，IND申请和手稿。目前还没有正式的机制，临床医生在这些专业可以获得这些技能和知识。为了满足这些需求，西北大学与芝加哥大学合作，提出了这一教育和职业发展计划。该计划将包括正式的课程，补充教育经验，参与基于实验室的癌症纳米技术项目，并参与癌症相关的放射学或放射肿瘤学临床研究。学员将有完成临床研究科学硕士（MSCI）的要求的选项。项目管理人员将包括项目主任盖勒·沃洛沙克博士、四名负责监督各种培训活动的其他教员、一个咨询委员会和一名项目管理员。虽然该计划针对的是刚刚完成放射学或放射肿瘤学实习的医学博士，但它也将对这些专业的执业临床医生开放。该计划将在罗伯特·H·西北大学Lurie综合癌症中心，得到了部门的大力支持。西北大学放射学和放射肿瘤学的教授。他是芝加哥大学放射学和放射与细胞肿瘤学的教授。该计划将与西北大学癌症纳米技术卓越中心有密切的联系。

DESCRIPTION (provided by applicant): This is the second revision of a proposal to establish an R25T cancer education and career development program, Cancer Nanotechnology in Imaging and Radiotherapy. Radiology and radiation oncology are clinical specialties that are heavily used for cancer diagnosis and treatment and that are likely to be revolutionized by advances in nanotechnology. For the fruits of nanotechnology research to benefit patients who are receiving radiology or radiation oncology services, there must be close collaboration between physical scientists, tumor biologists, and clinicians. The most important role of the clinician is to design and conduct clinical trials that assess the safety and efficacy of a newly developed nanomaterial. Fulfillment of this role requires not only clinical trials expertise, but also familiarity with the physical and chemical characteristics of the nanomaterial being tested and with the results of preclinical studies. Clinician input can also be critical in the conception of a nanotechnology study, in obtaining funding for such a study, in preclinical studies, especially those that involve animal imaging, and in dealing with regulatory agencies. To participate fully in the entire bench ? bedside process, radiologists and radiation oncologists must have a basic understanding of nanotechnology concepts and methodologies, a familiarity with nanotechology safety and regulatory issues, and an excellent grasp of the principles and practices of tumor biology. Furthermore, they need to be well-versed in the design and conduct of clinical trials, be familiar with small animal imaging, and be able to write research grants, IND applications, and manuscripts. There are presently no formal mechanisms by which clinicians in these specialties can acquire these skills and knowledge. To address these needs, Northwestern University, in conjunction with the University of Chicago, is proposing this education and career development program. The program will consist of formal coursework, supplementary educational experiences, participation in a laboratory-based cancer nanotechnology project, and participation in a cancer-related radiology or radiation oncology clinical study. Trainees will have the option of completing the requirements for a Master of Science in Clinical Investigation (MSCI). Program management will consist of the program director, Dr. Gayle Woloschak, four additional faculty members who will oversee various trainee activities, an advisory committee, and a program administrator. While the program is targeted to MDs who have just completed a residency in radiology or radiation oncology, it will also be open to practicing clinicians in these specialties. The program will operate under the auspices of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, with strong support from the Depts. of Radiology and of Radiation Oncology at Northwestern University and from the Depts. of Radiology and of Radiation & Cellular Oncology at the University of Chicago. The program will have strong links to Northwestern's Center for Cancer Nanotechnology Excellence.